Biblio

White AG, Watts GS, Lu Z, Meza-Montenegro MM, Lutz EA, Harber P, Burgess JL.  2014.  Environmental arsenic exposure and microbiota in induced sputum.. Int J Environ Res Public Health. 11(2):2299-313.

Roesly HB, Khan MR, Chen HDau Rw, Hill KA, Narendran N, Watts GS, Chen X, Dvorak K.  2012.  The decreased expression of Beclin-1 correlates with progression to esophageal adenocarcinoma: the role of deoxycholic acid.. Am J Physiol Gastrointest Liver Physiol. 302(8):G864-72.

Jandova J, Beyer TE, Meuillet EJ, Watts GS.  2012.  The matrix protein CCN1/CYR61 is required for α(V)β5-mediated cancer cell migration.. Cell Biochem Funct. 30(8):687-95.

Dvorak K, Watts GS, Ramsey L, Holubec H, Payne CM, Bernstein C, Jenkins GJ, Sampliner RE, Prasad A, Garewal HS et al..  2009.  Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.. Am J Gastroenterol. 104(2):302-9.

Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW.  2008.  Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.. Neoplasia. 10(5):450-61.

Watts GS, Tran NL, Berens ME, Bhattacharyya AK, Nelson MA, Montgomery EA, Sampliner RE.  2007.  Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma.. Int J Cancer. 121(10):2132-9.

Novak P, Jensen T, Oshiro MM, Wozniak RJ, Nouzova M, Watts GS, Klimecki WT, Kim C, Futscher BW.  2006.  Epigenetic inactivation of the HOXA gene cluster in breast cancer.. Cancer Res. 66(22):10664-70.

Ignatenko NA, Yerushalmi HF, Watts GS, Futscher BW, Stringer DE, Marton LJ, Gerner EW.  2006.  Pharmacogenomics of the polyamine analog 3,8,13,18-tetraaza-10,11-[(E)-1,2-cyclopropyl]eicosane tetrahydrochloride, CGC-11093, in the colon adenocarcinoma cell line HCT1161.. Technol Cancer Res Treat. 5(6):553-64.

Watts GS, Oshiro MM, Junk DJ, Wozniak RJ, Watterson S, Domann FE, Futscher BW.  2004.  The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.. Neoplasia. 6(3):187-94.

Ignatenko NA, Zhang H, Watts GS, Skovan BA, Stringer DE, Gerner EW.  2004.  The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells.. Mol Carcinog. 39(4):221-33.

Zheng XHui, Watts GS, Vaught S, A Gandolfi J.  2003.  Low-level arsenite induced gene expression in HEK293 cells.. Toxicology. 187(1):39-48.

Oshiro MM, Watts GS, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Domann FE, Futscher BW.  2003.  Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression.. Oncogene. 22(23):3624-34.

Crowley-Weber CL, Payne CM, Gleason-Guzman M, Watts GS, Futscher B, Waltmire CN, Crowley C, Dvorakova K, Bernstein C, Craven M et al..  2002.  Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate.. Carcinogenesis. 23(12):2063-80.